{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:48:54Z","timestamp":1762876134953,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.retram.2019.12.001","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T20:31:10Z","timestamp":1577219470000},"page":"17-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"68","author":[{"given":"Ivetta","family":"Danylesko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Chowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal J.","family":"Besser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elad","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avichai","family":"Shimoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.retram.2019.12.001_bib0005","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.retram.2019.12.001_bib0010","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.retram.2019.12.001_bib0015","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"Gokbuget","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.retram.2019.12.001_bib0020","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.retram.2019.12.001_bib0025","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/jnci\/djn276","article-title":"Trends in 5-and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990\u20132004","volume":"100","author":"Pulte","year":"2008","journal-title":"JNCI"},{"issue":"5","key":"10.1016\/j.retram.2019.12.001_bib0030","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.12442","article-title":"Predicting relapse risk in childhood acute lymphoblastic leukaemia","volume":"162","author":"Teachey","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.retram.2019.12.001_bib0035","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-Lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.retram.2019.12.001_bib0040","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.retram.2019.12.001_bib0045","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.retram.2019.12.001_bib0050","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.retram.2019.12.001_bib0055","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2019.12.001_bib0060","article-title":"A phase II study of the hyper-CVAD regimen in sequential combination with blinatumomab as frontline therapy for adults with B-cell acute lymphoblastic leukemia (B-ALL)","author":"Richard-Carpentier","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.retram.2019.12.001_bib0065","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9967","key":"10.1016\/j.retram.2019.12.001_bib0070","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.retram.2019.12.001_bib0075","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.retram.2019.12.001_bib0080","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.retram.2019.12.001_bib0085","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"224","key":"10.1016\/j.retram.2019.12.001_bib0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.retram.2019.12.001_bib0095","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"25","key":"10.1016\/j.retram.2019.12.001_bib0100","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.retram.2019.12.001_bib0105","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.681.681","article-title":"Durable remissions in children with Relapsed\/Refractory ALL treated with t cells engineered with a CD19-Targeted chimeric antigen receptor (CTL019)","volume":"126","author":"Grupp","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.retram.2019.12.001_bib0110","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ajh.25274","article-title":"Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia","volume":"93","author":"Jacoby","year":"2018","journal-title":"Am J Hematol"},{"journal-title":"Bone Marrow Transplant","year":"2019","author":"Kansagra","key":"10.1016\/j.retram.2019.12.001_bib0115"},{"key":"10.1016\/j.retram.2019.12.001_bib0120","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: leukemia escape after CD19-Directed t cell immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"issue":"12","key":"10.1016\/j.retram.2019.12.001_bib0125","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.retram.2019.12.001_bib0130","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.retram.2019.12.001_bib0135","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.15195","article-title":"Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB","volume":"181","author":"Li","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.retram.2019.12.001_bib0140","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.retram.2019.12.001_bib0145","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-16-1799","article-title":"Potent anti-leukemia activities of chimeric antigen receptor-modified t cells against CD19 in chinese patients with Relapsed\/Refractory acute lymphocytic leukemia","volume":"23","author":"Hu","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.retram.2019.12.001_bib0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.retram.2019.12.001_bib0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.retram.2019.12.001_bib0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","article-title":"Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab","volume":"8","author":"Kohnke","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.retram.2019.12.001_bib0165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.retram.2019.12.001_bib0170","doi-asserted-by":"crossref","DOI":"10.1097\/MPH.0000000000001440","article-title":"Treatment of recurrent refractory pediatric Pre-B acute lymphoblastic leukemia using inotuzumab ozogamicin monotherapy resulting in CD22 antigen expression loss as a mechanism of therapy resistance","author":"Paul","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"10.1016\/j.retram.2019.12.001_bib0175","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"10.1016\/j.retram.2019.12.001_bib0180","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study","volume":"1","author":"DeAngelo","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.retram.2019.12.001_bib0185","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40264-018-0760-1","article-title":"Benefit-risk assessment of blinatumomab in the treatment of Relapsed\/Refractory B-Cell precursor acute lymphoblastic leukemia","volume":"42","author":"Stein","year":"2019","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.retram.2019.12.001_bib0190","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318619300467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318619300467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:38:22Z","timestamp":1762821502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318619300467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S2452318619300467"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2019.12.001","relation":{},"ISSN":["2452-3186"],"issn-type":[{"type":"print","value":"2452-3186"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2019.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}